Compare AbbVie Inc (ABBV) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? AbbVie Inc trades at $249.52 (market cap $438.19B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.3. The key difference: AbbVie Inc pays a 2.79% dividend while Roundhill S&P 500 0DTE Covered Call Strategy ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | XDTE | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $263.58 | $44.76 |
52-Week Low | $197.38 | $36.00 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
XDTE trades at $39.46, up 0.65% with bullish technical signals from moving averages. The ETF generates weekly dividend distributions but faces scrutiny over yield sustainability and NAV erosion despite S&P 500 highs. Recent coverage highlights structural concerns about whether distributions represent true income or return of capital.
The fund offers high weekly income but carries significant risks including potential capital erosion and tax inefficiency. While technical momentum appears positive, fundamental concerns about the covered call strategy's long-term viability warrant caution for income-focused investors seeking sustainable returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
